The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in nonpancreatic neuroendocrine tumors (NET).
Monica M. Mita
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Edward M. Wolin
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Tim Meyer
Consultant or Advisory Role - Celgene (U)
Honoraria - Celgene
Research Funding - Celgene
John J. Nemunaitis
Research Funding - Celgene
Emily K. Bergsland
Consultant or Advisory Role - Celgene (U)
Amit Mahipal
Research Funding - Celgene
Lilly Wong
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Xiaoling Wu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
James Carmichael
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Rajesh Chopra
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Kristen Hege
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Johanna C. Bendell
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene